Evidence-Based Dermatology Intelligence

The Corneum

Free weekly analysis of trending skincare, wellness, and longevity treatments — evaluated against published human clinical evidence. No sponsorships. No affiliate links.

“Beneath the surface of every trend is the evidence.”

How We Rate

The Evidence Scale

Every analysis concludes with a clear evidence rating. No ambiguity, no waffling — just where the science stands.

Strong Evidence

Supported by Science

Multiple well-designed clinical trials with consistent results, clear mechanism of action, and reasonable safety data.

Promising

Worth Watching

Encouraging early-stage evidence. Some clinical data exists but studies may be small, short-term, or limited in design.

Insufficient Data

Too Early to Tell

Limited to no human clinical trials. Evidence may be preclinical, anecdotal, or contradictory.

Marketing Hype

Don’t Believe the Claims

Marketing claims significantly exceed the available evidence. May involve pseudoscience or cherry-picked data.

Latest Issue
Issue #056Special Report — Drug Repurposing
Marketing Hype

Anktiva: The Cancer Drug Cosplaying as a Longevity Breakthrough

An FDA-approved bladder-cancer immunotherapy, a billionaire's 'most important longevity drug of the decade,' zero human aging trials, and a fresh FDA warning letter.

Read the full analysis→
Archive

Every Issue

56 deep dives into trending treatments, evaluated against published clinical evidence.

#056Marketing Hype

Anktiva: The Cancer Drug Cosplaying as a Longevity Breakthrough

An FDA-approved bladder-cancer immunotherapy, a billionaire's 'most important longevity drug of the decade,' zero human aging trials, and a fresh FDA warning letter.

Special Report — Drug Repurposing
#055Promising

The Back Chain Advantage

Your kid's speed, injury risk, and athletic ceiling may come down to which muscles they load first. Here's how to tell — and what to do about it.

Special Report — Youth Performance
#054Insufficient Data

The Sinclair Eight

Forty-one trials, one Tally Health byline, and zero randomized evidence that moving an epigenetic clock means a longer life.

Special Report — Longevity Literature
#053Insufficient Data

Vitamin B1: The PMS Miracle Built From One Footnote

A single 80-woman trial reported a 35% dip in PMS symptoms. The internet rounded it up to 96%.

Deep Dive — Supplement Review
#052Insufficient Data

Klotho: The Longevity Protein With a Zero in the Human Column

Twenty percent longer life in mice. Sharper memory in eighteen monkeys. Completed human trials: zero. Price of the gene therapy anyway: $25,000.

Deep Dive — Longevity Review
#051Marketing Hype

Magnesium: The Mineral That Allegedly Fixes Everything

The internet's favorite supplement is real medicine for a few narrow problems and a marketing fantasy for the rest.

Deep Dive — Supplement Review
#050Insufficient Data

Taurine: The Energy-Drink Amino That Got a Longevity Promotion

One blockbuster mouse study, zero human longevity trials, and a 2025 rebuttal that quietly demoted it back to 'well-tolerated.'

Deep Dive — Supplement Review
#049Marketing Hype

Thermography: The Breast Scan That Misses Half the Cancers

Mammography's real flaws are worth arguing about. Swapping it for an infrared camera the FDA has warned about five times isn't the argument.

Deep Dive — Device Review
#048Promising

Bemotrizinol: The 25-Year Overnight Sensation

The FDA may finally bless the UV filter the rest of the world has used since the Clinton administration. But "proposed" isn't "approved," and it won't be on a shelf near you this summer.

Deep Dive — Regulatory Analysis
#047Strong Evidence

Icotrokinra: The Pill That Acts Like a Shot

The first oral psoriasis drug to clear skin like an IL-23 biologic — just don't confuse "biologic-level" with "best-in-class."

Deep Dive — Drug Review
#046Strong Evidence

Retatrutide: The 30% Drug

Eli Lilly's triple-agonist set a new weight-loss record across three Phase III trials — and surfaced a skin side effect the Phase 2 data never showed.

Deep Dive — Drug Review
#045Insufficient Data

MOTS-c: The Exercise Mimetic That Outlived Its Sponsor

Sixteen amino acids, one bankrupt biotech, and a Phase 1b that matched placebo.

Deep Dive — Drug Review
#044Insufficient Data

The Frog's Pharmacy

A bacterium from a Japanese tree frog's gut eliminated 100% of tumors in mice. The internet lost its mind. The science is more complicated.

Deep Dive — Preclinical Research
#043Promising

The Great Unbalding

New York Magazine declared hair loss science at "a real inflection point." Two drugs nobody's heard of are the reason why.

Deep Dive — Drug Review
#042Promising

The Anti-Trip That Rewires Your Brain

UC Davis engineered the hallucinations out of LSD and kept the neuroplasticity. One compound is now in human trials. The rest live in mice.

Deep Dive — Drug Review
#041Promising

Epigenetic Reprogramming

Three participants, one eye injection, and a researcher whose last breakthrough cost GlaxoSmithKline $720 million

Deep Dive — Drug Review
#040Promising

The Collagen Collapse

New 2025 research reveals semaglutide and tirzepatide directly suppress collagen-producing stem cells, trigger oxidative damage, and deplete dermal estrogen. The skin aging isn't just from weight loss.

Clinical Phenomenon
#039Insufficient Data

BPC-157: The Injury Repair Peptide

Paralyzed rats walked again. Severed tendons regrew. Then someone asked: has anyone tested this in humans?

Deep Dive — Peptide Review
#038Promising

When Tetracyclines Fail

80% of patients get the rash. 40% fail first-line treatment. Zero trials compare what comes next.

Deep Dive — Drug Review
#037Promising

New Hair Loss Drugs

Two genuinely novel mechanisms enter clinical trials — one with strong Phase 3 data, one with an elegant theory and a shaky dataset

Deep Dive — Drug Review
#036Insufficient Data

The Tamarind Microplastic Detox

A lab study removed 91% of microplastics from water using chemically modified tamarind — social media turned it into a dietary cure

Deep Dive — Ingredient Review
#035Promising

The Microbe That Builds Muscle

A gut bacterium linked to 29% greater grip strength in older adults — and how inulin-rich foods might feed it

Deep Dive — Supplement Review
#034Promising

Sofwave: The Comfortable Facelift

Seven parallel ultrasound beams, seven FDA clearances, zero randomized controlled trials, and a celebrity marketing machine running ahead of the science

Deep Dive — Device Review
#033Promising

Topical Fatty Acids for Hair Regrowth

A Cell Metabolism study finds monounsaturated fats regrow mouse hair in 20 days. Your scalp is not a mouse.

Deep Dive — Ingredient Review
#032Insufficient Data

Nattokinase vs. Statins

1,062 participants, a viral podcast clip, and a three-year gold-standard trial that says the opposite of what you've been told

Deep Dive — Supplement Review
#031Promising

Multimineral Supplements and Biological Aging

958 older adults, five epigenetic clocks, and a 2.6-month slowdown that Nature Medicine says matters — but your body might not notice

Deep Dive — Supplement Review
#030Promising

Ejaculation Frequency and Prostate Cancer

31,925 men, one self-reported question, and a headline that wrote itself

Clinical Phenomenon
#029Marketing Hype

Bras and Breast Sagging

An unpublished French study, a wellness influencer, and the peer-reviewed evidence they both ignored

Deep Dive — Category Review
#028Insufficient Data

Psilocybin and Longevity

One mouse study, zero human aging trials, and a viral tweet that skipped the dosing math

Deep Dive — Drug Review
#027Insufficient Data

Senolytics for Skin Aging

Zero human skin trials, one troubling tumor signal, and a supplement aisle full of sub-clinical doses marketed as the fountain of youth

Deep Dive — Supplement Review
#026Promising

Personalized Cancer Vaccines

A dying dog, a tech entrepreneur, and the 157-patient trial that actually matters

Special Report
#025Promising

Oral Collagen Peptides

23 randomized controlled trials show skin improvements. Zero of them were independently funded.

Deep Dive — Supplement Review
#024Insufficient Data

Topical Rapamycin

One 13-person trial, a $400/month cream, and a longevity community that skipped ahead of the evidence

Deep Dive — Drug Review
#023Insufficient Data

Hyperbaric Oxygen Therapy and Aging: The Pressure Chamber Fountain of Youth

One Israeli lab, one 35-person study, and a clinic chain built on the claim that sitting in a pressurized tube reverses biological aging

Deep Dive — Device Review
#022Insufficient Data

Salmon DNA: The Molecular Identity Crisis

A $285 million skincare trend built on injectable evidence — with zero human trials for the serums you're actually buying

Deep Dive — Ingredient Review
#021Promising

Low-Level Laser Therapy for Hashimoto's Thyroiditis

One Brazilian research group, 43 patients, and a claim that near-infrared light can replace your thyroid medication

Deep Dive — Device Review
#020Promising

VIR-5500: The Stealth Immunotherapy

82% biomarker response in a 58-patient trial sparked a $1.7 billion deal

Deep Dive — Drug Review
#019Insufficient Data

Procyanidin C1: The Grape Seed Longevity Pill

Zero human aging trials. One data integrity flag. A 150-year claim built entirely on mice.

Deep Dive — Supplement Review
#018Insufficient Data

Red Light Therapy and Arterial Plaque

One rabbit study, zero human trials, and a viral thread that skipped the fine print

Deep Dive — Device Review
#017Promising

Urolithin A: The Muscle Molecule With a Longevity Marketing Problem

A gut metabolite with real clinical data for strength and immunity — and a $125/month price tag built on claims the evidence doesn't support yet.

Deep Dive — Supplement Review
#016Promising

Retatrutide: The Triple Threat

Eli Lilly's triple-agonist delivers record-breaking weight loss and reverses fatty liver in early trials.

Deep Dive u2014 Drug Review
#015Strong Evidence

Adquey (Difamilast)

Japan has used this drug for three years. The U.S. just caught up.

Deep Dive — Drug Review
#014Insufficient Data

Antiparasitic Drugs for Cancer

Ivermectin and mebendazole: the studies the advocates don't cite

Special Report — Drug Repurposing
#013Insufficient Data

Methylene Blue for Skin

A 150-year-old dye with zero human skin trials

Deep Dive — Ingredient Review
#012Marketing Hype

The Peptide Crackdown

BPC-157 and TB-500: 544 studies, 1 human trial, 0 RCTs

Deep Dive — Regulatory Analysis
#011Strong Evidence

Tranexamic Acid for Melasma

A blood-clotting drug that may be the best melasma treatment you've never heard of

Special Report — Drug Repurposing
#010Insufficient Data

NMN / NAD+ Supplements

The longevity molecule caught between mouse data and FDA politics

Deep Dive — Supplement Review
#009Insufficient Data

At-Home RF & Microneedling

FDA safety warnings, recalled devices, and what actually works

Deep Dive — Device Review
#008Promising

PT-141 / Bremelanotide

The FDA-approved peptide that treats desire, not mechanics

Deep Dive — Drug Review
#007Promising

Microbiome Skincare

Strain-specific science vs. generic probiotic marketing

Deep Dive — Category Review
#006Insufficient Data

Bakuchiol

One 44-person study built a billion-dollar retinol alternative

Deep Dive — Ingredient Review
#005Strong Evidence

Ozempic Face

The facial aging side effect of GLP-1 drugs nobody warned you about

Clinical Phenomenon
#004Insufficient Data

PDRN / Salmon DNA

Korean beauty's hottest ingredient faces the evidence gap

Deep Dive — Ingredient Review
#003Promising

GHK-Cu Copper Peptide

The peptide with 50 years of data and a regeneration mythology

Deep Dive — Ingredient Review
#002Promising

Red Light Therapy

NASA wound healing tech turned wellness trend

Deep Dive — Device Review
#001Insufficient Data

Topical Exosomes

The $500 facial ingredient with a molecular identity crisis

Deep Dive — Ingredient Review
About

The Voice Behind
The Corneum

Dr. Maren Cole

Chief Science Editor

Dr. Maren Cole is an AI-generated editorial persona — not a real person. She represents the voice and analytical approach of The Corneum: rigorous, evidence-focused, and independent. All content is researched and written using AI tools, with references to published clinical literature.

The gap between what's marketed and what's proven is where people get hurt — financially and physically. The Corneum exists to close that gap.

Every issue evaluates a single trending treatment against published human clinical evidence. We search for meta-analyses, randomized controlled trials, and the studies that marketing materials conveniently forget to cite.

This newsletter is free. There are no sponsorships, no affiliate links, and no brand partnerships. Dr. Maren Cole is an AI-generated persona — not a real physician. All content is produced using artificial intelligence and should not be considered medical advice.

Free Weekly Newsletter

Get the evidence

One trending treatment. One deep dive. Every week. No spam, no affiliates, unsubscribe anytime.

Important Disclaimers

AI-Generated Content. All content on The Corneum, including articles, analyses, and evidence reviews, is generated using artificial intelligence. “Dr. Maren Cole” is a fictional AI persona and does not represent a real physician, dermatologist, or medical professional.

Not Medical Advice. Nothing published by The Corneum constitutes medical advice, diagnosis, or treatment recommendations. The information provided is for educational and informational purposes only. Always consult a qualified, licensed healthcare professional before making decisions about your health, skincare, or medical treatments.

No Guarantees of Accuracy. While we strive to reference published peer-reviewed studies, AI systems can make errors, misinterpret data, or present incomplete information. Study citations should be independently verified. Evidence ratings reflect AI analysis and may not represent the consensus of the medical community.

Use at Your Own Risk. You assume all risk associated with using any information from The Corneum. We are not liable for any damages, injuries, or losses resulting from reliance on content published here. Do not use this content as a substitute for professional medical judgment.

No Commercial Relationships. The Corneum has no sponsorships, affiliate relationships, or brand partnerships. We do not sell products or receive compensation for mentions or ratings.